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CHAPTER I 
 
 
INTRODUCTION 
Metabolic syndrome (MeS), a constellation of several risk factors including 
dyslipidemia, hypertension, central adiposity, and impaired fasting glucose, is also a 
condition associated with increased inflammation and hypercoagulation. Subjects with 
MeS also possess an increased risk of developing type 2 diabetes and coronary heart 
disease (CHD) (1). Emerging research shows  that obesity, hypertension, diabetes 
mellitus, dyslipidemia, smoking, aging, diets rich in saturated fats and reduced physical 
activity are the established risk factors for atherosclerosis and cardio vascular diseases 
(CVD) (2,3,4,5,6). All these metabolic and degenerative disorders are also characterized 
by inflammation and oxidant burden (7,8). Oxidative stress and inflammation play a 
pivotal role at all stages of atherosclerosis and the subsequent development of CHD 
(9,10). Hence, MeS subjects are at an increased risk for CVD like atherosclerosis. 
 The incidence of MeS is high among the US population (11). In the year 2000, 
approximately 64 million adults had MeS in US (12). Oklahoma is the 6th most obese 
state in US with 30.3% obesity prevalence (13). Also, according to the findings of the 
Strong Heart Study, the prevalence of MeS is high among the American Indians (43%) 
residing in Arizona, Oklahoma, North Dakota, and South Dakota (14). MeS, a condition 
characterized by increased oxidative stress and inflammation has a parallel association 
with overweight and obesity (15). Ever increasing prevalence of overweight and obesity 
predict further increase in MeS incidence in US. 
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Phytochemicals are a group of dietary bioactive compounds that were shown to 
have health promoting properties. Dietary bioactive compounds and phytochemicals have 
been shown to play a crucial role in attenuating biomarkers of oxidative stress and 
inflammation. According to NHANES 1999–2002 data on 24 hour dietary recalls, the 
mean flavonoid intake among US adults is 189.7 mg/day, with tea (157mg flavonoid/day) 
as the major flavonoid contributor. Almost 84 % of the total dietary flavonoid was 
contributed by tea with 21.3% US adults reported drinking tea on a daily basis. Daily 
total flavonoid intake of tea consumers was over 20 times than tea non consumers (697.9 
mg/day vs 32.6 mg/day) (16), indicating that tea is the major flavonoid source in US 
diets. 
Several epidemiological studies found an inverse association between dietary 
flavonoid intake and mortality. Large cohort and meta-analysis studies found a significant 
reduction in incidence of myocardial infarction (MI) and relative  risk of  death due to 
CVD with increase in green tea consumption (17,18,19).  In- vitro studies have suggested 
the role of flavonoids in cocoa, berries, tea, apples, onions, and red wine, in reducing the 
biomarkers of oxidative stress and inflammation (20). Epigallocatechin-3-gallate 
(EGCG), a major bioactive polyphenol present in green tea is a potent antioxidant and 
also an anti-inflammatory agent (21). Both green tea beverage and green tea extracts 
showed cardiovascular benefits by decreasing biomarkers of oxidative stress like Ox-
LDL (22) and inflammation like C-reactive protein (CRP) (23). The health benefits of 
green tea are mainly attributed to its flavonoid content that has anti-oxidant and anti-
inflammatory characteristics.  
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Even though green tea was studied extensively for its antioxidant and anti-
inflamamtory properties, most of the studies were done in animals and in cancer cell 
lines. Limited numbers of studies were done on cardiovascular benefits in individuals at 
risk like MeS subjects.  Since there is a limited research data on antioxidant and anti-
inflammatory health benefits of green tea flavonoids in MeS subjects, this study was 
conducted to assess the antioxidant and anti-inflammatory effects of chronic green tea 
flavonoid intake among subjects with MeS, a group more vulnerable to degenerative 
diseases. This study will also address the high burden of MeS in the state of Oklahoma. 
Green tea flavonoid supplementation may lower oxidative stress, thereby reducing the 
risks of atherosclerosis and other CVD in the subsequent years, in subjects with MeS. 
Since very little information is available in this field, our findings will add to the existing 
body of knowledge in the field of dietary bioactive compounds, including green tea 
flavonoids, and MeS. 
Purpose 
  There is limited information on the health benefits of green tea in MeS. The major 
purpose of this study is to assess the effects of chronic green tea flavonoid 
supplementation as a beverage or extract on features of MeS, biomarkers of oxidative 
stress and inflammation and plasma free catechin concentrations in MeS subjects. As 
there were not many comparison studies we want to compare the freshly brewed green 
tea beverage with green tea extract capsule supplementation in improving the 
components of MeS.  
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Null hypotheses:  
 The following null hypotheses are being tested in our study. 
1. Green tea beverage or green tea extract supplementation has no effect on 
anthropometric measures and features of metabolic syndrome in subjects with MeS. 
2. Green tea beverage or green tea extract supplementation has no effect on biomarkers 
of oxidative stress and inflammation in subjects with MeS. 
3. Green tea beverage or green tea extract supplementation has no effect on plasma 
catechin levels in subjects with MeS. 
CHAPTER II 
 
 
REVIEW OF LITERATURE 
Metabolic syndrome: prevalence, causes & consequences 
 Metabolic syndrome is one of the major public health problems and is found to 
be common in most countries of the world. In western countries like Americas, Europe 
and Asian countries like India, at least one-fourth of the adults are affected by this 
syndrome (24).  Nearly 50 million US adults aged ≥ 20 yrs had MeS in 1990 and it 
increased to approximately 64 million by the year 2000. NHANES III 1988-1999 and 
NHANES 1999-2000 surveys indicate a significant increase in MeS prevalence from 
23.1% to 26.7% (12).  MeS prevalence appears to be increasing because of the parallel 
increase in the obesity prevalence from 22% in 1988-1999 to 30.5% in 1999-2000. 
Another contributing factor for higher prevalence of MeS is aging of the population (24).   
Metabolic syndrome is a disorder that predisposes to the development of type 2 
diabetes and atherosclerotic diseases. This is mainly due to increased oxidative stress and 
inflammation that are associated with MeS (25). Hyperglycemia, a common feature of 
MeS, leads to the production of reactive oxygen species (ROS) like superoxide anion 
(O2−) and hydrogen peroxide (H2O2), through the activation of different pathways (26).  
Free radicals are molecules that contain one or more unpaired electrons and are 
highly reactive. Free radicals are produced as part of the normal metabolic reactions and 
are cleared by natural and dietary antioxidants present in the body (27). ROS react with 
nitric oxide and form more potent reactive nitrogen species (RNS) like peroxynitrite. 
Both ROS and RNS are toxic and affect many physiological processes like endothelial 
function and lipid peroxidation.  (28). ROS also cause oxidative damage to the vital cell 
 5
structures like cell proteins and DNA that can lead to cancer, atherosclerosis and heart 
diseases. Free radicals are not harmful all the time. They are also essential for microbial 
killing and immune function. Anti-oxidants are the substances that scavenge these 
radicals.   However, excessive levels beyond the endogenous anti-oxidant capacity to 
neutralize them are harmful (27). Green tea was shown to trap both reactive oxygen and 
nitrogen species and reduce oxidative stress (29). 
Role of oxidative stress and inflammation in CVD 
Oxidative stress, an imbalance between free radical formation and antioxidant 
status, is the major contributor to CVD, and inflammation is a manifestation of oxidative 
stress. Oxidative stress induces inflammation by acting on the pathways that generate 
inflammatory mediators like adhesion molecules and pro-inflammatory cytokines (27). 
Recent human studies have shown significant positive associations between oxidative 
stress and inflammation and indicators of vascular damage, like impaired endothelial 
function (30). Oxidative stress and inflammation also induce vascular smooth muscle cell 
(VSMC) activation and proliferation, angiogenesis, lipid peroxidation and platelet 
activation (31,32,33,28). All these initiate and promote atherosclerosis and increase CVD 
risk. Thus, a food rich in anti-oxidants like green tea may help in promoting 
cardiovascular health by reducing both inflammation and oxidant burden.         
Body has different mechanisms to get rid of the oxidant burden and to maintain 
the redox balance. One of such mechanisms is balance between prooxidant and anti-
oxidant enzymes. NAD(P)H oxidase, xanthine oxidase and myeloperoxidase are some of 
the ROS-generating oxidant enzymes and enhanced activity of these enzymes leads to 
oxidative stress. Endogenous antioxidant enzymes and vitamins like superoxide 
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dismutase, glutathione peroxidase, catalase, vitamin E and C scavenge or neutralize the 
excess free radicals and help in mitigating the oxidative stress and maintaining 
homeostasis (28). 
Biomarkers of oxidative stress and inflammation 
C-reactive protein (CRP) is the best validated inflammatory biomarker and a good 
predictor of future CVD events (33,34).  In addition to CRP, adiponectin, vascular cell 
adhesion molecule-1 (VCAM-1), tumor necrosis factor- α (TNF-α), interleukin-1 (IL-1), 
interleukin-18 (IL-18), soluble CD40 ligand (sCD40L), monocyte matrix 
metalloproteinase 9 (MMP-9) are other major biomarkers of  inflammation (35,34) 
Whereas, lipid peroxidation, oxidized-low density lipoprotein(Ox-LDL), urinary 8-
isoprostane levels are the oxidative biomarkers of CVD risk factors (36). 
CRP is an acute phase protein and its levels may increase up to 1000 fold during 
acute inflammation. CRP is an independent marker of systemic inflammation. Under 
laboratory conditions CRP is measured as high sensitivity CRP (hsCRP).  According to 
Li and Fang (2003), CRP is not only an indicator of inflammation, it also participates in 
the process of atherosclerosis by up regulating the expression of adhesion molecules, 
promoting the Ox-LDL uptake by macrophages, stimulating macrophages to release pro 
inflammatory cytokines like interleukin- 6 (IL-6) and TNF-α, activating vascular smooth 
muscle cells (VSMC) (37,38,32). Hence, CRP measurement in addition to the lipid 
profile will help in more accurate assessment and early detection of future CVD risk.  
It is well recognized that high levels of LDL is associated with CVD risk. 
Oxidative modification of LDL produces Ox-LDL in the arterial wall. Ox-LDL evokes 
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inflammatory response and participates in the process of atherosclerosis.  Circulatory Ox-
LDL levels is an indicator of oxidative stress and predictor of CVD risk (35,38). 
Nitric oxide (NOx) is a gaseous molecule with a very short half life of few 
seconds. NOx is produced from amino acid L-arginine by the action of nitric oxide 
synthase (NOS) (39). Three isoforms, endothelial NOS (eNOS), neuronal NOS (nNOS) 
and inducible NOS (iNOS) catalyze this reaction and are expressed in endothelial, 
neuronal and inflammatory cells respectively. Both eNOS and nNOS are constitutively 
expressed and produce NOx on demand at low physiological concentrations. This 
constitutive NOx is responsible for the regulation of many physiological processes like 
vasodilatation, cell communication and promoting endothelial integrity by preventing 
adhesion of inflammatory cells and adhesion molecules to endothelial cells.  
 Where as, iNOS is expressed in immune cells after cell activation by 
proinflammatory cytokines like tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-2 
and interferon gamma (IFN-γ) and results in over production of nitric oxide for a longer 
period of time (40). Abundance of NOx leads to the production of peroxy nitrite 
(ONOO−) by reacting with superoxide anion (O2−). ONOO− is a more potent cytotoxic 
reactive species Even though there is a greater production of NOx by iNOS under 
inflammatory conditions, its bioavailability and bioactivity will be reduced by formation 
of ONOO− (39,41).   
Green tea:  processing, storage, and stability 
Tea is one of the most widely used beverages worldwide. It is one of the most 
ancient Asian liquid foods. Camellia sinensis is the botanical name of tea plant and it 
belongs to Theaceae family. Tea leaves contain polyphenols and an enzyme polyphenol 
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oxidase. When tea leaves are chopped, this enzyme gets activated and oxidizes 
polyphenols. Different tea products like green tea, black tea and oolong tea are 
manufactured by subjecting fresh tea leaves to a series of treatments. (42). 
Green tea, most popular and more widely used tea in China, is made by exposing 
the cut leaves to hot steam or by applying high temperatures. This heat treatment prevents 
polyphenol oxidation by inactivating polyphenol oxidase (43,44).  The basic steps 
involved in green tea manufacture are plucking, heat treatment either by steaming or pan 
firing, rolling and high temperature air drying. The major aim of all these processes is to 
preserve the catechins in the final product. Variation in these processes results in 
compositional and aromatic differences among different green tea brands (42). Where as, 
black tea is produced by promoting enzymatic oxidation or fermentation and oolong tea 
by semi oxidation. Fermentation converts catechins to theaflavins and thearubigins and 
reduces catechin content in black tea (45). 
Tea composition varies with variety, age, position of the leaf, climate and season. 
Young leaves like leaf bud and first leaf are richest in catechins. However the leaves used 
for green tea manufacture are relatively low in catechin content compared to the ones 
used for black tea (42). This may be due to the great commercial value for black tea than 
other teas. 
Green tea chemistry  
The principal flavonoid phytochemicals present in green tea are called catechins. 
Catechins are polyphenolic plant metabolites  that belong to flavonoid group, particularly 
to flavan-3-ols. Catechins are colorless water soluble compounds with astringent taste. 
Epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gallate (ECG) 
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and epicatechin (EC) are the major catechins found in green tea. Catechins are phenols 
composed of three benzene rings with hydroxyl groups. The number of hydroxyl groups 
indicates the antioxidant capacity.  Catechins constitute about 30% of green tea by dry 
weight (42). EGCG is the major green tea catechin and it accounts for 50-80% of the total 
catechin content (46). 
Digestion, absorption, and metabolism of catechins  
Flavonoids in nature are always glycosides with a sugar moiety, but catechins 
occur as aglycones.  Intact flavonoid aglycones reach the small intestine following 
ingestion. They don’t need any transporters and   diffuse into enterocyte. In the 
enterocyte they undergo conjugation reactions and reach the liver for further metabolism. 
All these metabolites are released into systemic circulation, reach different parts of the 
body and excreted through urine and feces (47). 
 However some of the conjugated catechins from liver are transported back to 
small intestine through bile via enterohepatic circulation. Catechin conjugates cannot 
diffuse through the intestinal epithelium hence they reach colon, where colonic 
microflora deconjugate them and releases aglycones. Aglycones may be reabsorbed or 
undergo further metabolism (48). Microflora convert catechins to phenyl valerolactones 
and then to phenolic acids. Catechin metabolites may be absorbed in the colon or 
excreted through feces (46).    
Three types of metabolic pathways methylation, glucuronidation and sulfation 
have been identified for all catechins. Liver, small intestine and colon are the major 
organs where catechins are extensively metabolized (46). Small intestine has lower 
specific activity than liver in the methylation. Methylation occurs in cytosol and is 
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catalyzed by catechol-O-methyltransferase (COMT). The products of methylation are 
mono or dimethylated catechins. Glucuronidation occurs in the microsomes of liver and 
small intestine. Glucuronosyl transferases (UGT) catalyze the conjugation and form 
glucuronides. Sulfation is carried out by sulfotransferases (SULT) in liver and intestinal 
cytosol (49). All these catechin and catechin metabolites reach liver through portal vein 
and then reach systemic circulation. They undergo phase I and phase II metabolism at 
various sites in the body and finally excreted through urine and feces (48). 
Both EGC and EC were absorbed much faster than EGCG. Delayed 
absorption may be due to the extra gallate moiety in EGCG. EGCG was better absorbed 
when given through oral route than through intra gastric administration in rats, and also 
the absorption is 3.6 fold higher when it given as green tea beverage rather than a pure 
EGCG supplement. Another important finding is that EGCG was less readily eliminated 
from body when given in the form of green tea beverage compared to supplement. This 
may be due to the competition for elimination enzymes like sulfotransferase and 
glucuronosyltransferase that result in inhibition of EGCG elimination. Not all the 
catechins are excreted in a similar way. EGCG is excreted mainly through bile whereas 
EGC and EC are excreted through both bile and urine (50).  
Green tea catechin stability 
Several factors like pH, temperature and the presence of other substances 
influence the stability of green tea catechins (GTC) in either freshly prepared green tea or 
processed tea drinks (51). A study conducted on eleven brands of dry tea leaves and 
fourteen brands of canned or bottled tea drinks showed that GTC are more stable in 
aqueous solutions at room temperature and at low pH.  More than 90% of GTC was lost 
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when pH was increased to 5. Approximately 23% of the catechin was lost when tea was 
autoclaved at 120 °C for 20 min, whereas the loss was only 15 % in traditional tea drink 
prepared with freshly boiled water. Sucrose, citric acid and ascorbic acid, the common 
ingredients of bottled tea drinks, showed different effects at different times on catechin 
stability (52).  
High temperatures employed during the processing of tea drinks promote 
epimerization of catechins. Epimerization affects catechin bioactivity and heat 
epimerized catechins, gallo catechin (GC), gallo catechin gallate (GCG) are slightly less 
efficient anti-oxidants than their precursors (53). These studies indicate the superiority of 
freshly brewed tea drinks over processed tea drinks in terms of catechin content, 
bioactivity and stability. 
Pharmacokinetics of green tea catechins 
Lee et al (2002) administered a single oral dose of green tea (20 mg solids/ kg 
body wt) or EGCG (2 mg/kg body wt) to human subjects. The maximum plasma 
concentrations of EGCG, EGC, and EC with green tea were 77.9, 223.4, and 124.03 
ng/ml, respectively. The elimination half lives were 3.4, 1.7 and 2 hr respectively. All the 
catechins reached peak concentration between 1.3 and 1.6 hr. These pharmacokinetic 
parameters indicate that green tea catechins are rapidly absorbed and eliminated. EGCG 
stays in the system for a relatively longer period of time compared to other catechins. 
This may be due to the additional gallate moiety or due to the competition for elimination 
enzymes. In plasma, most of the EGCG was present in free form where as EGC and EC 
were found in conjugated form (54).  
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Bioavailability 
Green tea polyphenols (GTP) are less bioavailable.  Molecular size, molecular 
weight, processing and mode of transport are some of the factors that influence the GTP 
bioavailability (55). Information on bioavailability and biomarkers of green tea 
consumption is not yet clear. Wang etal (2008), found a dose-dependent increase in green 
tea plasma catechin levels, particularly EGCG and ECG. They conducted a phase II 
intervention trial with 500 or 1000 mg of green tea polyphenols among 124 healthy adults 
for 3 months. In plasma, EGCG existed in free form unlike other catechins. They found a 
predominance of free polyphenols like EGCG than sulfated and glucuronidated 
conjugates. Both ECG and EGCG are the reliable biomarkers of green tea consumption in 
blood (56).  
EGCG is the most abundant and most potent catechin of green tea. However, its 
bioavailability is limited due to the poor absorption from small intestine. In addition to 
poor intestinal absorption, active efflux by microsomes (57), pahse II bio-transformation 
and microbial degradation in the colon are some of the factors that contribute to enhanced 
elimination of catechins from the system and reduced bioavailability (58). Chow et al 
(2003) conducted a pharmacokinetic study on green tea polyphenols and suggested that 
up to 800 mg /day of green tea polyphenols in the form of supplements is well tolerated 
and safe for healthy individuals (59).  
Bioavailability can be increased by taking the green tea supplements on an empty 
stomach (60).  In an effort to improve the bioavailability of EGCG, Lambert and 
colleagues (2006) prepared a paracetylated EGCG derivative (AcEGCG).  Acetylation is 
the process of replacing the hydrogen atoms with acetyl groups thus making the hydroxyl 
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groups unavailable for phase II transformation (61). The authors found improved cell 
uptake and increased intracellular AcEGCG concentration. The plasma area under curve 
was significantly higher for AcEGCG (465.0 µg/ml) compared with EGCG (194.6 
µg/ml), and the t1/2 and bioactivity were also increased for AcEGCG (62). 
Though acetylation improved the bioavailability of EGCG, we may not predict 
the same for other catechins. Different green tea catechins and metabolites have different 
pharmacokinetic behaviors due to their structural differences and presence or absence of 
gallate moiety. More research is needed on the pharmacokinetics of catechins and 
catechin conjugates.  
Anti-oxidant and anti-inflammatory effects of green tea 
Green tea has both anti-oxidant and anti-inflammatory properties. Green tea was 
more effective against lipid oxidation in cell membranes compared to roasted, oolong and 
black tea (63). A green tea catechin supplementation study conducted among 40 healthy 
Japanese adults found significant decrease in Ox-LDL levels from 9.56 ± 9.2 to 7.76 ± 
7.7 U/mL. Subjects in catechin group received green tea extract (Polyphenon 70S) 
capsules containing 500 mg of catechin (equivalent to the dosage found in 6 to 7 cups of 
green tea) for 4 weeks. This study showed a significant (11.7%) reduction in Ox-LDL 
levels with green tea consumption (64).  
Regular consumption of tea containing 690 mg of catechin per bottle of oolong 
tea promoted weight loss and fat loss. It also reduced oxidative stress by inhibiting the 
formation of malondialdehyde modified LDL (MDA-LDL). MDA-LDL is a marker of 
unstable atherosclerotic CVD. These results indicate the possible role of catechins in 
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obesity prevention and improvement in obesity related disorders like MeS and Type 2 
diabetes (65). 
Another study with green tea supplementation for 2 weeks (8g/day) in young 
smokers significantly improved endothelial function, as measured by flow-mediated 
vasodilatation, thereby preventing future cardiovascular events in these subjects (66). 
Where as green tea consumption for 4 weeks reduced intracellular adhesion molecule-1 
(ICAM-1), and oxidized LDL levels in adult smokers (67). Smoking is associated with 
increased oxidative stress and increased risk for CVD. Green tea may improved the CVD 
risk factors through its anti-oxidant and anti-inflammatory properties. 
Anti-Obesity and hypolipidemic effects of green tea 
Nagao and colleagues (2007) conducted a clinical trial to study the body fat and 
CVD risk reducing effects of green tea extract high in catechins. Japanese men and 
women (n=240) with visceral fat-type obesity received either catechin rich (583 mg/can) 
green tea or catechin poor (96 mg/can) green tea for 12 weeks. There was a non-
significant, greater decrease in all the anthropometric indices of body fat like body 
weight, body mass index, body fat mass, visceral and subcutaneous fat areas in the 
catechin group than in the control group. They also found a decrease in systolic blood 
pressure (SBP) and low-density lipoprotein (LDL) cholesterol among catechin rich group 
(68). 
The possible mechanisms by which green tea catechins reduce body fat are related 
to increased energy expenditure and fat oxidation and sympathetic nerve induced 
thermogenesis (69,70). Catechins induce hypolipidemic effects by inhibiting the rate 
limiting enzyme in the cholesterol synthesis and suppression of fatty acid synthase gene 
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expression (71). The insignificant results in the Nagao et al (2007) study may be due to 
the catechin dosage that is not enough to show any marked changes in the tested 
parameters.  
Green tea effects on nitric oxide  
Inflammation induces excessive NOx production, which in turn increases 
oxidative stress by forming RNS. Several clinical studies found an association between 
high levels of serum/plasma nitric oxide and metabolic syndrome features (72,40,73).  A 
large population based study conducted among 3505 subjects with MeS showed a 
significantly higher serum NOx values (31.9 Vs 29.8 µmol/L) compared to controls. It 
also showed a direct association between number of metabolic risk factors and serum 
NOx levels (72). 
Maejima et al (2001) showed higher plasma NOx levels in type II diabetic 
subjects. Plasma NOx levels were also correlated with the presence of hypertension and 
microvascular complications (73).  Another clinical study also found significantly higher 
serum NOx concentrations among overweight and obese women. They also found 
positive correlations of serum insulin with both NOx and TNF-α concentrations. 
Summarizing the findings, all these clinical studies indicate that metabolic and 
degenerative diseases are associated with increased levels of iNOS induced NOx, 
resulting in impaired endothelial function, insulin secretion and increased risk for CVD. 
Green tea, an antioxidant rich beverage, showed a direct scavenging of NOx and   
O2−   in-vitro. Catechins with gallate moiety and with tri-hydroxyl groups in their structure 
like EGCG and ECG showed greater free radical scavenging capacity (29). In a cell 
culture study, green tea extract inhibited iNOS mRNA expression, iNOS protein and 
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NOx production in human alveolar and colon epithelial cells in a concentration dependent 
manner (74).  
 Another cell culture study on human osteoarthritis chondrocytes found that EGCG 
(100 µM) inhibits NOx production. Cells were stimulated with IL-1β alone (2ng/ml) and  
IL-1β+ EGCG. IL-1β is a pro-inflammatory cytokine that increases NOx production by 
enhancing the iNOS expression. Treatment with EGCG significantly reduced the IL-1β 
induced NOx production (75). Hence EGCG may help in improving inflammatory 
diseases like CVD. It seems that green tea is effective in reducing iNOS induced NOx 
levels both by acting as an antioxidant and anti-inflammatory agent. Previous studies also 
indicate that green tea works at transcriptional level to inhibit iNOS production. 
Green tea is a catechin rich beverage. Though it improves health through its anti-
oxidant properties, it also prevents diseases and promotes cardiovascular health through 
different other mechanisms like mitigating inflammation, inhibiting transcription of 
inflammatory cytokines, inhibiting activation of inflammatory mediators, promoting 
endothelial function and through anti-obesity and  hypolipidemic effects. Most of the 
green tea studies were conducted in animal models and cancer cell lines. Existing green 
tea clinical studies were conducted in healthy subjects in Asian countries like China and 
Japan. Due to the differences in dietary pattern and relatively longer green tea exposure 
in Asian subjects, we may not apply the previous study findings to Western subjects. 
Most often, anti-oxidative and anti-inflammatory effects of green tea were investigated in 
healthy subjects. There is a gap in knowledge with regards to anti-oxidative and anti-
inflammatory effects of green tea in MeS subjects in western countries like US. As the 
prevalence of obesity and MeS were constantly increasing in US there is an immediate 
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need to address the problem. Hence, we are investigating the effects of green tea on 
features of metabolic syndrome and biomarkers of oxidative stress and inflammation in 
MeS subjects. 
 
CHAPTER III 
 
 
METHODOLOGY 
 
Subjects 
 28 subjects with metabolic syndrome were recruited through the General Clinical 
Research Centre (GCRC) at Oklahoma Health Sciences Center at Oklahoma City. 
Subjects were randomly assigned to the following 3 groups. 
• Control group (usual diet + 4 cups of water) 
• Green tea beverage group (4 cups green tea/day and usual diet) 
• Green tea extract group (amount of EGCG ~green tea beverage and usual diet + 4 
cups of water) 
  
Flyers were posted at the GCRC Oklahoma Health Sciences Center, Oklahoma City 
and interested subjects were screened to examine if they fit the study criteria. Upon 
qualification, they were enrolled into the study.  A telephone questionnaire was used for 
initial screening. Subjects who qualified were randomized to any one of the three groups 
using a GCRC randomization sheet. The informed consent was administered prior to the 
screening blood draw. 
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 Research plan  
28 subjects identified with Metabolic Syndrome  
 
 
                               Subjects were randomly assigned to the following groups  
 
 
                       Control (n=12)    Green tea beverage (n=11)   Green tea extract (n=5)    
 
 
 
         8 week intervention period 
 
 
 
          Subjects return at 2, 4, 6, & 8 weeks for control, supplement groups; 
 regular visits for tea beverage goup  
 
 
 
 Blood draws at baseline, 4, & 8 weeks were used to measure  
plasma catechin levels and nitric oxide levels  
 
 
  Subjects compensated at the end of the study or pro-rated at $30/visit 
 
 
 
All subjects were consented and entered into the study following the approval of 
the institutional review board (IRB) at Oklahoma State University and the corresponding 
human ethics committees at University of Oklahoma Health Sciences Center.  
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Inclusion criteria 
According to the NCEP guidelines, subject should possess any three of the  
following features to fall in the category of metabolic syndrome: Waist circumference ( ≥ 
102 cm in men & ≥ 88 cm in women), triglycerides ≥ 150 mg/dL, HDL (< 40 mg/dL in 
men; < 50mg/dL in women), blood pressure ≥ 130/85mm Hg, fasting glucose                 
(≥ 100mg/dL). Adult subjects ≥ 21 years of age, but with normal Hb, WBC, platelets, 
liver, renal, and thyroid function tests and met at least three features of metabolic 
syndrome  were included in the study.  Subjects on stable medications were included. 
Exclusion criteria 
  Any form of pre-existing disease, e.g. cancer, heart disease, diabetes, liver or 
renal disorders, anemia, pregnancy and lactation, women on hormone replacement 
therapy, taking mega doses of antioxidants/fish oil supplements,  abnormal Hb (normal 
range: 12.0-18.0 g/dL), WBC (normal range: 4.0-11.0 K/mm3), or platelets (140-440 
K/mm3), hypo/hyperthyroidism (normal range  for thyroid stimulating hormone: 0.35-
4.940 units/mL, abnormal liver enzymes ( normal range for AST: 7-40 units/L; ALT- 10-
45 units/L), abnormal kidney function ( normal creatinine: females- 0.7 – 1.2 mg/dL; 
males- 0.8-1.2 mg/dL; normal BUN: 1-59 Years – 7-18 mg/dL; > 59 Years- 8-21 mg/dL), 
smoking, and drinking alcohol (>1oz/day) were excluded from the study. Any subject 
with deviations from the normal range of Hb, WBC, platelets, liver enzymes, BUN, 
creatinine or TSH, during the study period were discontinued from the study. Both males 
and females, as well as individuals from any ethnic group, who qualify were included in 
the study. For women, the blood draws and anthropometric measurements were 
conducted between day 6 & 15 of their menstrual cycle to control for the effect of 
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hormone on study variables. Children were not included in the study. 
Upon qualification, the subjects were randomized to the control and intervention 
groups as mentioned in Research Plan. Fasting blood draws were done by a certified 
phlebotomist, at screening, 4, and 8 weeks of the study subjects in the green tea beverage 
group were supplemented on a daily basis since the study participants in this group were 
recruited on- campus at OUHSC. Subjects were compensated $ 30 per visit and these 
visits include screening, 2, 4, 6 and 8 weeks of the study. 
Anthropometric and blood pressure  
Anthropometric measurements were obtained by trained staff members at the 
GCRC. Height, weight, blood pressure, WC, and BF% were measured at screening, four, 
and eight-week visits. Systolic and diastolic blood pressure was collected in mmHg with 
Spot Vital Signs Device (Welch Allyn, Skaneateles Falls, NY). Waist circumference was 
taken from subjects at the superior iliac crest with the Gulick II Tape Measure (Vital 
Signs, Gay Mills, WI). Body fat percentage was determined through bio-electrical 
impedance assay (BIA) with the Bodystat 1500 (Bodystat Ltd, Isle of Man, Great 
Britain). 
Sample collection  
Blood samples were collected in heparinized tubes, and also in vials containing 
EDTA, and serum separator tubes. Serum and plasma samples were separated by 
centrifugation, flushed with nitrogen and stored at -800C for subsequent analyses of 
plasma Ox-LDL, CRP, NOx and catechins.  
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Reagents 
Green tea catechin standards epicatechin (EC), epicatechingallate (ECG), epigallo 
catechin (EGC) were purchased from Sigma-Aldrich (St Louis, MO), and 
epigallocatechingallate (EGCG) from Calbiochem (La Jolla, CA). Green tea from 
Bigelow (Fairfield, CT) and green tea supplements from Solaray (Park City, UT) were 
purchased. All the chemicals were HPLC grade. Acetonitrile and methanol were obtained 
from Pharmco-Aaper (Brookfield, CT). Phosphoric acid from EMD Chemicals 
(Gibbstown, NJ), perchloric acid from Sigma-Aldrich (St Louis, MO) and potassium 
carbonate from J.T.Baker (Phillipsburg, NJ) were purchased. For serum total nitric oxide 
Nitrate/nitrite colorimetric assay kit from Cayman Chemical (Ann Arbor, MI), for plasma 
Ox-LDL mercodia oxidized LDL competitive ELISA kits from Mercodia, Uppasala, 
Sweden, quantikine human C-reactive protein from R and D systems (Minneapolis, MN) 
were used. 
Catechin standards 
All four major green tea catechins: EC, EGC, ECG, and EGCG 1 mg each, were 
individually dissolved in 1 mL of methanol: water (1:1, v/v) and were sonicated for 20 
min in amber coloured micro centrifuge tubes. Catechin standard stock solutions were 
further diluted to obtain 200, 100 and 50 µg/mL concentrations. Standard calibration 
curves were constructed for all the four catechin standards. Catechin concentrations were 
calculated from the peak area by using the equation for linear regression obtained from 
the calibration curve. 
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Green tea samples 
 Both green tea leaves and green tea extract capsules were analyzed for their 
catechin content. 100 mg of dried tea leaves from Bigelow green tea bags were weighed 
and dissolved in methanol:water (1:1, v/v) in 100 ml volumetric flask and sonicated for 
20 min. the same procedure was followed for the green tea supplement. Catechin content 
of each sonicated sample was analyzed by running through HPLC.  
HPLC conditions 
 The HPLC system consisted of a waters 600 pump, 717 autosampler, and 2447 
dual λ absorbance detector with Empower software (Waters Corporation, Milford MA). 
The mobile phase consists of two solvents; solvent A (freshly prepared 0.2% phosphoric 
acid) and solvent B (100 % acetonitrile). These two solvents were used under binary 
linear gradient conditions as follows: 0-5 min, 100% A; 5-15 min, 90-85% A & 10-15% 
B; 15-25 min, 85-80% A   & 15-20% B; 25-30 min, 100% A with a flow rate of 0.5 
mL/min. All samples 50 µl injection volumes were filtered (0.22 µm) and analyzed on 
Waters symmetry C18 (100 mm - 4.6 mm, 3.5 µm) column. The sample run time was 30 
min. The column temperature was maintained at 21°C.The absorbance at 200 nm was 
used for detection and quantification of catechins from standards, green tea samples and 
plasma samples. 
Plasma free catechins 
  Plasma free catechins were analyzed by the LC-UV modified   method developed 
by Masukawa etal (2006). To 250 µl of the plasma thawed just prior to use, 25 µl 6M 
perchloric acid and 125 µl acetonitrile were added. The mixture was vigorously mixed 
for 2 min with a vortex mixer in a polypropylene tube. The mixture was  kept at 5 °C for 
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30 min, and was then centrifuged at 20,000×g for 5 min or 13,000 x g for 10 min at 5 °C 
in a eppendorf Centrifuge 5417R (Hamburg, Germany). The supernatant and 100 µl 
0.75M potassium carbonate solution were mixed moderately for 30 s. Insoluble 
potassium perchlorate in the tube was precipitated by centrifugation at 20,000×g for 5 
min or 13,000 x g for 10 min At 5 °C. The resulting supernatants were analyzed by 
HPLC analysis (90). 
Plasma Ox-LDL   
 
 Mercodia Oxidized LDL (Mercodia Uppsala Sweden) competitive ELISA was 
used to determine LDL oxidation.  This assay is based on the monoclonal antibody 4E6. 
A fixed amount of oxidized LDL is bound to the microtiter well. This oxidized LDL 
competes with the oxidized LDL in the sample. The absorbance was then measured at 
450 nm and read spectrophotometrically. Data was analyzed using a calibration curve for 
each assay. 
Human C-reactive protein 
 CRP was measured by quantitative sandwich immuno assay. Microplates were 
pre-treated with CRP specific monoclonal antibody. When samples and standards are 
pipetted into the wells any CRP present in the sample binds to the immobilized antibody. 
Adding substrate solution produces colour which is proportional to CRP in the sample. 
Intensity of the colour was measured at 450 nm. 
Serum total nitric oxide (NOx) 
Determination of NOx radical is difficult as it has a very short half-life of 10-16 
seconds. NOx rapidly converts to nitrate (NO3− ) and nitrite (NO2− ). Recent studies 
indicate that these inorganic anions can be converted to bioactive NOx and can be 
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considered as storage pool of NOx (76). Hence plasma nitrite and nitrate concentrations 
are used as indicators for NOx radical formation. Serum total nitrate and nitrite levels 
were measured by using the Nitrate/Nitrite calorimetric kit (Cayman chemical, MI, USA) 
based on Griess reaction. This method is based on two steps. In the first step nitrate is 
converted to nitrite by nitrate reductase and in the the second step nitrite is converted to 
deep-purple azo compound with the addition of Griess reagent I and II. Serum total nitric 
oxide concentration was determined by photometric quantification of azo compound. 
Serum samples were ultrafiltered by using 30 kDa molecular weight cut-off (MWCO) 
filters  (Amicon, Ultracel YM 30 membrane), pre-rinsed with Millipore water. 
Ultrafiltration reduces background absorbance and improve color formation with Greiss 
reagent. Approximately 300 µl of the serum sample was taken into the filters and was 
centrifuged at 14,000 g for 20 minutes at room temperature. 40µl of the filtrate was added 
to duplicate wells and were diluted with equal amount of assay buffer. Enzyme cofactor 
mixture and nitrate reductase mixture 10µl each were added to all the standard and 
sample wells. The plate was covered, gently shaked and incubated at room temperature 
for 3 hours. After incubation 50 µl each of Greiss reagent R1 and R2 were added to 
standard and sample wells. It was allowed to develop color for 10 minutes at room 
temperature. Blank wells contained 200µl of assay buffer. After 10 min of color 
development at room temperature, the absorbance was measured on a multi-detection 
microplate reader (Synergy HT, Vermont, USA) at 540 nm. Each sample was assayed in 
duplicate wells. Standard curves were prepared with known concentration of nitrate stock 
standard (200µM). Care was taken while pipetting to avoid the air bubbles that interfere 
with the absorbance. The detection limit for total nitric oxide assay is > 2.5µM.    
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Statistical methods:  
All measures had descriptive statistics calculated and graphs drawn to look for 
outliers. Outliers due to data errors were corrected where possible or removed. Analyses 
were completed with and without outliers and their influence on the results discussed. 
Pair wise differences (green tea versus control and green tea extracts versus control) 
between the groups at baseline were assessed using student t-tests. 
Changes in measurements over the eight week study period were assessed by 
calculating the difference between the pre and post-intervention measurements. The 
differences calculated for the green tea and green tea extract groups were then 
conditioned on their respective control; the difference seen in the control participant was 
subtracted from the difference seen in each corresponding green tea extract participant 
within age and gender matched trio. These conditional differences for the green tea and 
green tea extract groups were assesses as being different from zero using student t-tests. 
All statistical tests were two-tailed with significance level set at 0.05. Significance levels 
were not adjusted for multiple hypotheses testing, rather, the results were reviewed for 
consistencies, SPSS for windows (version 15.0, SPSS Inc., 2006) was used for the 
statistical calculations.
CHAPTER IV 
 
 
RESULTS 
 
Baseline characteristics and metabolic syndrome features 
A total of 28 subjects with at least 3 metabolic syndrome features were included 
in the analysis. Baseline characteristics and features of metabolic syndrome of the 
subjects were shown in Table 2. The mean age of the subjects ranged from 40 - 45 yrs. 
Subjects were randomly assigned to control (n=12), green tea beverage (n=11) or green 
tea extract (n=5) groups. Waist circumference, fasting blood glucose, triglycerides (TG), 
high density lipoprotein cholesterol (HDL), systolic and diastolic blood pressure were the 
metabolic syndrome features used for the selecting criteria. Subjects in all the three 
groups were obese with mean BMI ranging from 37.4 to 41.5.  Many of the subjects were 
on anti hypertensive drugs. Hence, their systolic (SBP) and diastolic (DBP) blood 
pressures were lower than the MeS cut-off points of > 130 mm Hg and > 85 mm Hg 
respectively.  In all three groups, almost half of the subjects were on medications with the 
highest percentage in green tea beverage group (85.7%). Medication use was 
significantly higher (p<0.05) in green tea beverage and green tea extract groups 
compared to controls.  Angiotensin converting enzyme (ACE)-inhibitors, calcium-
channel blockers and beta-blockers were the most common forms of blood pressure 
medications used by the subjects.  Apart from medication use, there were no significant 
differences in baseline parameters among the three groups. 
 
 
 28
Anthropometric measures and blood pressure  
 Eight weeks of green tea supplementation showed a significant decrease in body 
weight and BMI in the green tea beverage group when compared with controls (P<0.05). 
Anthropometrics and blood pressure measurements at baseline and at eight weeks are 
shown in Table 3. Body weight reduced by 2.3 kg in green tea beverage group. Green tea 
extract group also showed a non-significant decrease in body weight by 1.9 kg. A greater 
decrease in SBP (from 135.6 to 126.3 mmHg) and a slight reduction in DBP (from 83.7 
to 79.0 mm Hg) were observed in green tea beverage group only versus controls, though 
not statistically significant. In contrast, both green tea extract and control groups showed 
an increase in DBP. 
Biomarkers of oxidative stress and inflammation 
 Ox-LDL, nitric oxide and CRP were measured as biomarkers of oxidative stress 
and inflammation (Table 4). There were no significant differences in any of these three 
measures between the study groups at baseline and at 8 weeks. However, we observed a 
decreasing trend in both Ox-LDL (P<0.1) and NOx (P<0.1) in green tea beverage group 
compared to baseline. Green tea supplementation decreased Ox-LDL levels from 109 to 
87.5 U/L in green tea beverage group. A non-significant decrease in NOx concentrations 
was observed in both green tea beverage and green tea extract groups. It decreased by 
31.2 % in beverage group and 11.5 % in extract group compared to baseline while NOx 
levels increased by 17 % in control group. CRP levels also showed a non-significant 
decrease from 6.2 to 5.8 mg/L and 6.3 to 5.8 mg/L in green tea beverage and green tea 
extract groups, respectively, whereas, CRP levels increased from   5.6 to 5.7 mg/L in the 
control group.  
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Plasma free catechins 
 The four major green tea catechins EGC, ECG, EGCG and EC were measured in 
the plasma by HPLC and as shown in Table 5. We were not able to detect EC in many 
plasma samples. In addition to this, standard errors were greater than mean values. 
Because of these inconsistent results in EC levels, we excluded this data from analysis. 
There were no significant differences in any of the catechins among the three groups at 
baseline and at 8 weeks.  The plasma free catechin concentrations were lower than those 
found in actual green tea beverage samples and green tea extract capsules. Table 1. 
summarizes the amounts of four major catechins in both green tea beverage and green tea 
extract. Highest plasma concentrations were observed for EGC and lowest were found for 
EGCG. 
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TABLES 
Table 1. Catechin and caffeine composition of green tea beverage and green tea 
extracts 
 
 
 
Catechins (mg) Green tea beverage¹  (1 cup ≈ 8 fl oz) 
Green tea extract¹  
(1 capsule) 
Total Catechins (mg) 232.0 (100) 435.0 (100)
EGCG 110.0 (47.4) 230.0 (52.8)
EGC 55.0(23.7) 120.0 (27.6)
ECG 45.0 (19.4) 60.0 (13.8)
EC 22.0 (9.5) 25.0 (5.8)
Caffeine 2.24 1.8
 
 
 
 
 
 
¹ Percentage of total catechin in parentheses.  
 Total catechin concentration was defined as the sum of EGCG, EGC, ECG and EC 
values. EGCG- epigallocatechin gallate, EGC- epigallocatechin, ECG- epicatechin 
gallate, EC- epicatechin 
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Table 2. Baseline characteristics and metabolic syndrome features of the subjects in 
 all the treatment groups  
 
               Variables 
 
C (n=12)
 
GT (n=11) 
 
GTE (n=5)
 
Age (yrs) 44.6± 3.2 45.3±3.0 40.0±4.2
Male 1 1 1
Female 11 10 4
Body weight (kg) 104.6±6.9 108.6±4.4 116.5±8.3
BMI ( kg/m2)  37.4±2.8 38.6±1.5 41.5±2.1
Waist circumference (in) 43.0±2.0 44.2.0±1.0 49.7±3.7
Glucose (mg/dL) 88.8±4.4 89.3±3.4 84.8±2.8
TG (mg/dL) 129.2±21.1 168.0±27.1 148.4±38.4
HDL (mg/dL) 40.8±1.8 40.3±2.2 37.7±5.0
SBP (mm Hg) 129.5±2.8 135.6±5.9 127.4±6.4
DBP (mm Hg) 78.7±2.1 83.7±3.5 80.8±2.7
Medication users (%) 45.4 85.7* 60*
 
Values are Mean ± SE 
* p<0.05, significantly different from the control 
C- Control group, GT- Green tea beverage group, GTE- Green tea extract group 
BMI- Body mass index, TG- Triglycerides, HDL- High density lipoprotein, SBP- 
Systolic blood pressure, DBP- Diastolic blood pressure 
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Table 3. Anthropometric measures and features of metabolic syndrome at baseline 
and at 8 weeks of the study subjects 
 
 
Variables Week Contrlol (n=12) GT (n=11) GS (n=5) 
Body weight (Kg) 0 104.6 ± 6.9 108.6 ± 4.4 116.5 ± 8.3 
 8 105.2 ± 6.9 106.1 ± 4.0 * 41.5 ± 2.1 
Body weight change 
(Kg) GT vs C            -    - 2.3 ± 0.7*           - 
 GTE vs C            -            -    - 1.9 ± 0.6 
BMI ( kg/m2) 0 37.4 ± 2.8 38.6 ± 1.5 49.7 ± 3.7 
 8 37.6 ± 2.8 37.7 ± 1.4 * 41.0 ± 2.0 
Body fat (%) 0 45.7 ± 3.1 46.5 ± 3.1  47.7 ± 2.2 
 8 45.7 ± 3.4 46.2 ± 2.6 47.5 ± 2.0 
Waist circumference 
(in) 0 43.0 ± 2.0 44.2.0 ± 1.0 49.7 ± 3.7 
 8 42.7 ± 1.8 45.2 ± 1.5 48.3 ± 3.0 
HDL (mg/dL) 0 40.8 ± 1.8 40.3 ± 2.2 37.7 ± 5.0 
 8 39.7 ± 1.7 41.5 ± 2.4 36.2 ± 4.2 
Glucose (mg/dL) 0 88.8 ± 4.4 89.3 ± 3.4 84.8 ± 2.8 
 8 85.9 ± 4.7 88.8 ± 2.5 83.3 ± 6.4 
SBP (mm Hg) 0 129.5 ± 2.8 135.6 ± 5.9 127.4 ± 6.4 
 8 128.0 ± 2.8 126.3 ± 5.3 128.0 ± 3.8 
DBP (mm Hg) 0 78.7 ± 2.1 83.7 ± 3.5 80.8 ± 2.7 
 8 80.2 ± 2.8 79.0 ± 3.7 81.6 ± 3.9 
 
 
Values are Mean ± SE 
* Changes at 8 weeks significantly different from control (p<0.05) 
** Decrease in trend at 8 weeks compared to baseline (p<0.1) 
GT- Green tea beverage group, GTE- Green tea extract group 
BMI- Body mass index; calculates as kg/m2, TG- Triglycerides, HDL- High density 
lipoprotein, SBP- Systolic blood pressure, DBP- Diastolic blood pressure 
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Table 4. Biomarkers of oxidative stress and inflammation at  
     Baseline (0) and at 8 weeks of green tea supplementation 
 
Biomarker Week C (n = 12) GT (n = 11) GTE (n = 5) 
Ox-LDL (U/L) 0 102 ± 11.5 109 ± 5.4 91 ± 9.1 
 8 94.6 ± 8.1 87.5 ± 5.2* 93 ± 9.2 
Nitric oxide (µM) 0 18.6 ± 4.6 22.7 ± 3.9 25.8 ± 2.6 
 8 21.8 ± 6.5 15.6 ± 7.9* 22.8 ± 3.7 
CRP (mg/L) 0 5.6 ± 1.5 6.2 ± 2.7 6.3 ± 3.8 
 8 5.7 ± 1.7 5.8 ± 3.1 5.8 ± 2.9 
 
Values are Mean ± SE  
* (P<0.1) compared to baseline  
C- Control group, GT- Green tea beverage group, GTE- Green tea extract group, 
Ox-LDL- Oxidized low density lipoprotein, CRP- C-reactive protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34
 35
 
Table 5. Plasma free catechin concentrations of the metabolic syndrome subjects at 
baseline (0) and after 8 weeks of green tea supplementation  
 
Green tea 
catechin Week C (n=12) GT (n=11) GTE (n=5) 
EGC  (µg/ml) 0 65.87 ± 15.87 70.78 ± 19.09 77.89 ± 16.98
 8 69.87 ± 17.65 73.76 ± 17.98 75.98 ± 22.98
ECG  (µg/ml) 0 18.98 ± 9.75 26.97 ± 11.76 28.96 ± 15.98
 8 26.86 ± 8.95 31.96 ± 13.67 33.65 ± 14.76
EGCG (µg/ml) 0 10.4 ± 8.64 15.87 ± 9.56 12.76 ± 8.98
 8 10.76 ± 5.66 20.45 ± 8.98 18.95 ± 7.98
 
Values are Mean ± SE  
No significant differences between groups (p>0.05) 
C- Control group, GT- Green tea beverage group, GTE- Green tea extract group  
EGC-Epigallocatechin, ECG- Epicatechin gallate, EGCG- Epigallocatechin gallate  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER V 
 
 
DISCUSSION AND CONCLUSION 
 This is an eight week randomized, single blind controlled study investigating the 
effects of green tea polyphenols as green tea beverage or green tea extract in MeS 
subjects. We investigated the effects of green tea supplementation on anthropometrics, 
MeS features and biomarkers of oxidative stress and inflammation. We found a 
significant reduction in body weight with green tea beverage. This study also found non-
significant improvements in metabolic syndrome features and biomarkers of oxidative 
stress and inflammation with green tea beverage supplementation.  
Anthropometrics and features of metabolic syndrome 
 Green tea has been shown to exert anti-obesity effects in several clinical studies. 
The major mechanisms by which green tea reduces body weight are related to increased 
energy expenditure and fat oxidation (77,70,78). Auvichayapat et al (2008) showed a 
significant decrease in body weight following 12 weeks of green tea extract 
supplementation. Pure EGCG supplementation per se increased fat oxidation in obese 
men (70). Where as, Hsu et al (2008) did not find any difference in body weight with 
green tea extract supplementation in obese women. Exact reasons for this null effect were 
not known. However, they were not able to detect any of the green tea catechins in 
plasma samples collected after 12 hrs. This may partially explain the absence of any 
effect on body weight (23). A large cross section study conducted in Japan found that 
increased green tea consumption was associated with decreased serum cholesterol, LDL 
cholesterol and triglycerides and increased HDL cholesterol concentrations (79). This 
indicates that green tea can improve components of MeS. In our study, subjects were 
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obese (grade-II and grade-III) with BMI values ranging from 37.4 to 41.5 kg/m2. Green 
tea supplementation reduced body weight significantly in green tea beverage group only. 
We also observed a non-significant increase in HDL cholesterol with green tea beverage 
compared to baseline. 
Biomarkers of oxidative stress and inflammation 
Ox-LDL, NOx and CRP are significantly elevated in subjects with MeS compared 
to controls in several studies. Hence, we selected these three markers for our study. 
Oxidative stress is characterized by increased levels of ROS (27).  As it is difficult to 
measure free radicals because of their unstability, Ox-LDL is measured as an indicator of 
oxidative stress (80). Recent clinical studies have reported higher concentrations of Ox-
LDL in subjects with metabolic syndrome (81) and with components of metabolic 
syndrome like hyperlipidemia and abdominal obesity (3). In contrast, Sjogren et al (2005) 
found no increase in Ox-LDL concentrations in MeS subjects. However, the percentage of 
subjects classified as having MeS (≥ 3 MeS features) was only 8%. This relatively low 
percentage reduces the power to interpret the data (82). In-vitro studies demonstrated that 
green tea polyphenols can inhibit Cu(2+)  induced LDL oxidation (83).  Sung et al (2005) 
found a significant reduction of 21.1% in plasma Ox-LDL levels versus baseline in young 
men (28-42 yrs) supplemented with 4 cups of green tea/day for 4 weeks (22). Inami et al 
(2007) found a significant reduction in Ox-LDL (11.7%) levels in Japanese adults with 4 
weeks of green tea extract supplementation.  In our study, we found a non-significant 
(19.7%, p<0.1) decrease in Ox-LDL in green tea beverage group only compared to 
baseline. However, we did not find any decrease in Ox-LDL with green tea extract. In 
contrast, we observed a 2.1% increase in Ox-LDL in green tea extract group. The amount 
 37
of the green tea beverage (22) and green tea extracts (64) used in the previous studies is 
equal to the amount that we used in our study. There might be differences in total catechin 
content and composition of the green tea beverage used in different studies. In addition the 
subjects in the previous study (Sung et al, 2005) are healthy and relatively young (28-42 
yrs) compared to the subjects in our study. Also, the baseline Ox-LDL concentrations (69.5 
U/L) of these subjects are less than the concentrations (100.6 U/L) that we found in our 
subjects. Healthy young subjects versus metabolic syndrome subjects might have 
contributed to the differences in the significance of our study results.    
 Nitric oxide is a gaseous molecule produced by NOS family enzymes. Under 
inflammatory conditions iNOS is stimulated and results in excessive production of NOx 
(40).   Asl et al (2008) found significantly higher serum NOx levels in MeS subjects 
(with at least 3 MeS features) compared to controls (72). Obese and overweight women 
also showed higher levels of both NOx and TNF-α. TNF-α is a pro-inflammatory 
cytokine that activates iNOS.  A positive correlation between these two biomarkers in 
subjects with metabolic disorders indicates that high NOx concentrations were 
contributed by TNF-α induced iNOS (40,84). Singh et al (2002) found a significant 
reduction in IL-1β induced NOx production in human osteoarthritis chondrocytes treated 
with EGCG (75).  Basing on the existing literature it may be concluded that subjects with 
MeS in our study have high levels of inflammation induced NOx. As green tea showed 
anti-inflammatory properties in addition to anti-oxidant abilities, we wanted to examine 
effects on NOx levels in MeS subjects.  Reported clinical studies have not investigated 
the effects of green tea flavonoid supplementation on NOx concentrations in MeS.  Thus, 
to our knowledge this is the first study to show the decreasing trend in NOx levels with 
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green tea beverage supplementation. In our study, serum NOx levels were decreased in 
both the green tea supplementation groups with greater decreases in beverage group 
(31.2%).  Our study participants had slightly lower NOx levels ranging from 18.6 µmol/L 
- 25.8 µmol/L compared to the previous study (26.1 µmol/L - 27.4 µmol/L) by Asl et al 
(2008) in Iran in MeS subjects (72). In our study most of the subjects were women, in 
addition to this, differences in age, diet and physical activity and environment might have 
influenced the NOx levels (85). 
CRP is an acute phase protein that increases under inflammatory conditions. CRP 
is an independent predictor of CVD risk. Younger subjects (25.86 yrs) with MeS showed 
significantly higher levels of CRP compare to controls. CRP levels increased with 
increase in number of MeS features (86). Nah and Lee (2006) found a positive correlation 
between hsCRP and fasting glucose, SBP; and negative correlation with HDL cholesterol 
in MeS subjects (87). Dietary anti-oxidants have an effect on CRP. In a seven year 
Swedish cohort study, hsCRP levels were negatively associated with dietary intakes of 
ascorbic acid and α-tocopherol (88). It indicates that oxidative stress and inflammation 
are positively associated. Chronic green tea extract (decaffeinated) supplementation 
significantly reduced CRP levels in hemodialysis patients compared to controls (23). This 
study clearly demonstrates the anti-inflammatory effects of green tea, as CRP levels 
increased and reached control levels in the same subjects during washout period. 
However, both acute and chronic green tea consumption did not show any effect on CRP 
levels among healthy smokers (67,89). The confounding factors like smoking and high 
caffeine content of green tea in the later studies limit the interpretation of results. In our 
study, the mean CRP levels of the subjects in all the three groups at baseline ranged from 
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5.6- 6.3 mg/L.  These high CRP concentrations (> 3 mg/L) confirm that our subjects are 
with elevated levels of inflammation and at high risk for future CVD. A non-significant 
decrease in CRP levels in green tea beverage and green tea extract may be due to small 
sample size and short duration (2 months) of supplementation. Four cups of green tea in 
our study and in a previous study by Sung et al (2005) may not be enough to cause a 
significant decrease in CRP levels. 
As most of the previous studies were conducted in young healthy subjects and 
smokers comparing the study results with our findings is difficult.  Metabolic syndrome 
is a condition associated with increased oxidative stress and inflammation. Hence they 
may require higher doses of green tea and supplementation for longer periods that may 
cause the same significant improvements in biomarkers of oxidative stress and 
inflammation as observed in hemodialysis patients (23).  
Plasma free catechins 
    Plasma free catechin concentrations were not significantly different between 
groups at baseline and at 8 weeks.  However, we observed a pattern that is similar to most 
green tea pharmacokinetic studies (90,58). Catechins were eluted in the order of EGC, 
EC, EGCG and ECG. Gallated catechins like EGCG and ECG eluted at the end. The 
relatively longer elution time is due to the presence of gallate moiety that increases their 
size compared to non-gallated catechins. Green tea catechins are rapidly absorbed and 
eliminated. Over 90% of the catechins were cleared from the body with in 8 hrs of 
consumption (91). Hsu et al (2008) were not able to detect EGCG in obese subjects after 
12 hrs over-night fast (23). However, Wang et al (2007) detected all four major green tea 
catechins in 12 hr overnight-fast blood samples (92). We were also able to detect the 
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green tea catechins in plasma even after 12 hrs of green tea consumption. This indicates 
the longer retention times in the body in certain subjects. When compared among the four 
green tea catechins, EGC was found in higher concentration and EGCG in lower 
concentrations in plasma. Similar findings were observed in pharmacokinetic studies 
conducted by Yang et al (1998) in healthy humans (91). Gallate moiety and tri-hydroxyl 
groups in EGCG structure reduce the intestinal absorption and might have contributed to 
the low plasma levels.     
Limitations: 
 Complete monitoring of the supplement intake was not possible. Subjects in the 
green tea beverage group consumed only 2 cups of green tea every day in GCRC under 
the supervision of a study dietitian. Consumption could not be monitored for the 
remaining 2 cups taken at home. In green tea extract group, pill count was considered for 
measuring compliance. However, it is difficult to measure the compliance in human 
subjects. 
 Lack of information on diet and physical activity is another major limitation. 
Physical activity was not monitored during the study period. Seasonal changes may cause 
changes in dietary intakes and physical activity levels.  Access to dietary data will allow 
us to correlate the dietary components like lipids, anti-oxidants, vitamins and sodium to 
the tested variables like body weight, Ox-LDL, CRP, NOx and blood pressure. Even 
though subjects were instructed to maintain their usual diet and physical activity, there is 
a possibility of alteration in these parameters.   
 Like many green tea studies, information was not complete for nutrient and 
phytochemical composition of the green tea samples used in the study. This might be 
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another possible limitation. Some of the minerals and vitamins like zinc and vitamin C 
have anti-oxidant properties. Data on mineral and vitamin content of green tea samples in 
addition to the catechin composition might have helped us in understanding the 
differential effects between green tea beverage and green tea extract.   
Medication use among the subjects is another limitation. A significantly higher 
percentage of subjects were on medication in green tea beverage and green tea extract 
groups. This might have masked the effects of green tea flavonoid supplementation.  
The relatively small sample size and short period of supplementation might have 
contributed to the insignificant results. 
Implications 
 Green tea beverage may help in reducing obesity prevalence as it showed 
significant weight loss in subjects with MeS. The study finding implies that, weight 
reducing effects were contributed by green tea catechins as both green tea beverage and 
extract used were decaffeinated. Green tea beverage may help in reducing oxidative 
stress and inflammation as it showed a decreasing trend in Ox-LDL and NOx 
concentrations. Hence, green tea may be beneficial not only for MeS, but also for other 
diseases like cancer. Our study indicates that green tea catechins can be detected in the 
body even after 12 hrs. Green tea is the most widely consumed beverage in the world. 
Any health promoting effects found with green tea consumption may benefit a wide 
range of population globally. 
Future studies 
           As of now, only plasma free catechin levels are used as biomarkers of green tea 
polyphenol bioavailability. This may not be an accurate marker, as green tea polyphenols 
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undergo phase II biotransformation in the body and produce catechin conjugates. Future 
studies are needed to explore more accurate green tea polyphenol biomarkers taking into 
consideration the level of conjugation of catechins. Future studies should be conducted 
with larger sample and for longer duration in order to see significant effects in 
biomarkers of oxidative stress and features of MeS. The present study found a difference 
between green tea beverage and green tea extract in improving components of MeS, 
oxidative stress and inflammatory indicators. Also, future studies should focus on the 
compositional changes between different green tea supplements. 
Hypotheses  
 The present study investigated the effects of green tea supplementation on 
anthropometrics, features of metabolic syndrome, biomarkers of oxidative stress and 
inflammation and plasma free catechin concentrations.  
• We reject the null hypothesis: chronic green tea beverage or green tea extract 
supplementation has no effect on anthropometric measures and features of 
metabolic syndrome. There was a significant decrease in body weight and BMI in 
green tea beverage group versus controls (p<0.05). 
• We fail to reject the null hypothesis: chronic green tea beverage or green tea 
extract supplementation has no effect on biomarkers of oxidative stress and 
inflammation in subjects with MeS.  
• We fail to reject the null hypothesis: chronic green tea beverage or green tea 
extract supplementation has no effect on plasma free catechin levels in subjects 
with MeS. 
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Conclusion 
 Eight weeks of decaffeinated green tea beverage supplementation significantly 
reduced body weight compared to controls. No significant changes in metabolic 
syndrome features and biomarkers of oxidative stress and inflammation were observed in 
any of the groups with green tea supplementation. However, we found a decreasing trend 
for Ox-LDL and NOx concentrations and increasing trend for HDL levels in the green tea 
beverage group only. This indicates that green tea beverage may help in reducing 
oxidative stress and inflammation in subjects with MeS. This study confirms the anti-
obesity effects of green tea, as the effects were observed in subjects without any change 
in diet and life style. Future studies with larger sample size and longer duration are 
necessary to explain the findings of our study.  
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Scope and Method of Study:  Green tea, rich in anti-oxidants, particularly 
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beverage (4 cups/day, 440 mg EGCG) or green tea extract (2 capsules/day, 460 
mg EGCG) groups for 2 months. 
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beverage group vs control after 8 weeks of supplementation. Green tea catechins 
were found in plasma samples collected after over-night fast. This indicates that 
catechins may present in the system for longer periods of time.  Green tea 
supplementation with higher doses for longer periods is necessary to explore the 
findings of our study.  
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